Outcome of Hepatocellular Carcinoma Detected During Surveillance: Comparing USA and Japan

Toyoda, Hidenori; Hiraoka, Atsushi; Olivares, Jocelyn; Al-Jarrah, Taim; Devlin, Pauline; Kikuchi, Yuji; Maeda, Atsuyuki; Yopp, Adam C.; Parikh, Neehar D.; Singal, Amit G.

doi:10.1016/j.cgh.2020.10.033

Cited by 9 publications

(4 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, while a US-based strategy was successful in some settings, such as Japan, where screening methods incorporating the α-FP, α-FP-L3, and DCP biomarkers allowed for the detection of a significant percentage of tumours measuring less than 2 cm [221,222], it may be challenging to spread in others. Likewise, as a result, more than half of the Japanese with a diagnosis of HCC had undergone surgery or local ablation therapy, implying that increasing HCC screening uptake in other contexts may spare meaningful national public health resources.…”

Section: Discussionmentioning

confidence: 99%

“…Nevertheless, GALAD may still be an effective tool in HCC screening and surveillance, especially in diagnosing a subset of patients with a small tumour and negative α-FP and DCP [210,222], but it may not be the best strategy in the other cases [218]. Indeed, Sachan A et al recently commented in a letter that, in the absence of clear superiority to current surveillance strategies, as well as the limitations of using the GALAD score universally in all HCC patients, its routine use for HCC screening and surveillance may no longer be feasible [218].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Updating the Clinical Application of Blood Biomarkers and Their Algorithms in the Diagnosis and Surveillance of Hepatocellular Carcinoma: A Critical Review

Shahini

Pasculli

Solimando

et al. 2023

IJMS

View full text Add to dashboard Cite

The most common primary liver cancer is hepatocellular carcinoma (HCC), and its mortality rate is increasing globally. The overall 5-year survival of patients with liver cancer is currently 10–20%. Moreover, because early diagnosis can significantly improve prognosis, which is highly correlated with tumor stage, early detection of HCC is critical. International guidelines advise using α-FP biomarker with/without ultrasonography for HCC surveillance in patients with advanced liver disease. However, traditional biomarkers are sub-optimal for risk stratification of HCC development in high-risk populations, early diagnosis, prognostication, and treatment response prediction. Since about 20% of HCCs do not produce α-FP due to its biological diversity, combining α-FP with novel biomarkers can enhance HCC detection sensitivity. There is a chance to offer promising cancer management methods in high-risk populations by utilizing HCC screening strategies derived from new tumor biomarkers and prognostic scores created by combining biomarkers with distinct clinical parameters. Despite numerous efforts to identify molecules as potential biomarkers, there is no single ideal marker in HCC. When combined with other clinical parameters, the detection of some biomarkers has higher sensitivity and specificity in comparison with a single biomarker. Therefore, newer biomarkers and models, such as the Lens culinaris agglutinin-reactive fraction of Alpha-fetoprotein (α-FP), α-FP-L3, Des-γ-carboxy-prothrombin (DCP or PIVKA-II), and the GALAD score, are being used more frequently in the diagnosis and prognosis of HCC. Notably, the GALAD algorithm was effective in HCC prevention, particularly for cirrhotic patients, regardless of the cause of their liver disease. Although the role of these biomarkers in surveillance is still being researched, they may provide a more practical alternative to traditional imaging-based surveillance. Finally, looking for new diagnostic/surveillance tools may help improve patients’ survival. This review discusses the current roles of the most used biomarkers and prognostic scores that may aid in the clinical management of HCC patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Updating the Clinical Application of Blood Biomarkers and Their Algorithms in the Diagnosis and Surveillance of Hepatocellular Carcinoma: A Critical Review

Shahini

Pasculli

Solimando

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…With superior surveillance, Japanese centers have been able to find 63.5% of 19,536 HCCs in a 2-year period with a solitary nodule, with 56.6% being less than 3 cm [ 22 ]. In a study of 1,797 patients diagnosed with surveillance from two US and two Japanese centers, the Japanese patients were diagnosed with smaller tumor size and less advanced stage and were more likely to undergo curative treatment [ 23 ]. Median survival time was also longer in patients from Japan.…”

Section: Discussionmentioning

confidence: 99%

Management of hepatocellular carcinoma in patients who are 70 years or older

Lee

Karasaki

Ogihara

et al. 2022

Surgery Open Science

View full text Add to dashboard Cite

“…The other barrier is the low quality of surveillance for patients with NAFLD. Although the Japanese surveillance system is well developed for the early detection of HCC, 8…”

mentioning

confidence: 99%

Editorial: non‐viral hepatocellular carcinoma surveillance—an increasingly severe public health issue. Authors' reply

Toyoda

Kariyama

Hiraoka

2022

Aliment Pharmacol Ther

Self Cite

View full text Add to dashboard Cite

show abstract

Outcome of Hepatocellular Carcinoma Detected During Surveillance: Comparing USA and Japan

Cited by 9 publications

References 34 publications

Updating the Clinical Application of Blood Biomarkers and Their Algorithms in the Diagnosis and Surveillance of Hepatocellular Carcinoma: A Critical Review

Updating the Clinical Application of Blood Biomarkers and Their Algorithms in the Diagnosis and Surveillance of Hepatocellular Carcinoma: A Critical Review

Management of hepatocellular carcinoma in patients who are 70 years or older

Editorial: non‐viral hepatocellular carcinoma surveillance—an increasingly severe public health issue. Authors' reply

Contact Info

Product

Resources

About